Todas las investigaciones
AutorizadoExploratorio terapéutico (Fase II)Intervencionista

An Open-Label Study to Assess the Long-Term Safety and Tolerability of ML-007C-MA in Adult Participants with Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis

This ongoing study is investigating a new medication called ML-007C-MA. It's for adults living with Alzheimer's disease who are also experiencing hallucinations (seeing or hearing things that aren't there) and delusions (strong beliefs that aren't true). The main purpose of this study is to closely watch for any side effects or problems with the drug over a long period. Researchers want to make sure the treatment is safe and that people can take it without too much discomfort. This is considered a 'Phase II' study, which means it's an earlier stage of research designed to gather more information about safety and how well the drug might work, building on initial findings.

De un vistazo

Estado
Autorizado
Fase
Exploratorio terapéutico (Fase II)
Patrocinador
Maplight Therapeutics Inc.
Objetivo de inscripción
85
Inicio
27 de mayo de 2026

¿De qué trata este estudio?

This research study is looking at a new medication called ML-007C-MA. It's designed for people who have Alzheimer's disease and are also experiencing distressing symptoms like hallucinations and delusions. Hallucinations mean seeing, hearing, smelling, tasting, or feeling things that aren't real, while delusions are strong, false beliefs that a person holds, even when shown evidence they're not true. These symptoms can be very upsetting for people with Alzheimer's and their families. This study is trying to find a way to help reduce these experiences safely.

The main goal of this particular study is to understand the long-term safety of ML-007C-MA and whether people can comfortably take it over time. This means doctors will be very carefully looking out for any side effects, both minor and serious. They will also assess how well the medication might be helping with the hallucinations and delusions, and how it impacts quality of life and daily activities.

This is an 'open-label' study, which means both the participants and the study team will know that the active drug is being given. This is part of the ongoing process of developing new medicines, ensuring they are safe and effective for patients who need them.

Puntos clave

  • This study is for adults with Alzheimer's disease who have hallucinations or delusions.
  • It aims to check the long-term safety and whether the new drug, ML-007C-MA, is well-tolerated.
  • Participants will have regular health checks and tests.
  • It's a Phase II study, focusing on safety and early signs of effectiveness.
  • La participación es voluntaria, y puedes retirarte en cualquier momento.

¿Quién puede ser elegible?

To be considered for this study, you would need to be an adult, aged 18 years or older. The study is open to both men and women.

The most important requirement is that you must have been diagnosed with Alzheimer's disease and are currently experiencing hallucinations or delusions linked to your condition. These are the specific symptoms the study medication aims to help with.

There would also be other detailed medical criteria that the study doctors would check to make sure the study is right and safe for you. For example, they might look at your overall health, other medicines you are taking, and specific medical test results.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. ¿Tienes 18 años o más?
  2. Do you have a diagnosis of Alzheimer's disease?
  3. Are you currently experiencing hallucinations or delusions linked to your Alzheimer's?
  4. ¿Puede asistir a visitas regulares a la clínica?
  5. Are you willing to take a new study medication?
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

If you decide to take part in this study, you would receive the study medication, ML-007C-MA, for a period of time. You would have regular visits to the clinic where the study team would monitor your health very closely. These visits would involve various assessments, such as reviewing any side effects you might be experiencing, checking your medical history, and performing physical examinations.

You would also have blood tests, heart rhythm checks (ECG), vital sign measurements (like blood pressure and pulse), and weight checks. Additionally, you would complete questionnaires to assess your symptoms, memory, and how you are feeling generally. The total duration of your participation, including follow-up appointments, would be explained fully by the study team.

Riesgos y beneficios potenciales

Taking part in any medical study has potential benefits and risks. You might benefit from receiving a new treatment that could potentially help with your hallucinations and delusions, and you would be closely monitored by medical professionals. On the other hand, there's always a risk of experiencing side effects from the study medication, which could range from mild to more serious. The research team will explain all known risks to you. Remember, participation is completely voluntary, and you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (9)

Algunas ubicaciones de los sitios son aproximadas. Estamos mejorando esto — por favor verifique con el equipo de prueba antes de viajar.
  • —
    No verificado
    Italia
  • —
    No verificado
    Polonia
  • —
    No verificado
    Chequia
  • —
    No verificado
    Portugal
  • —
    No verificado
    Bulgaria
  • —
    No verificado
    Francia
  • —
    No verificado
    Eslovaquia
  • —
    No verificado
    Rumania
  • —
    No verificado
    Hungría

Preguntas comunes

What are hallucinations and delusions in Alzheimer's?

Hallucinations mean seeing or hearing things that aren't really there. Delusions are strong, false beliefs that a person holds, even when shown they're not true. Both can be distressing for people with Alzheimer's.

What is a 'Phase II' study?

Phase II means it's an earlier stage of research. The main goals are to gather more information about how safe the new drug is, what doses might work best, and to see if it shows signs of being effective for the condition it’s meant to treat.

¿Qué significa 'etiqueta abierta'?

Open-label means that everyone involved – both the people taking part in the study and the doctors and nurses – will know that the active study medication is being given, rather than a dummy pill (placebo).

Will I have to pay to join this study?

No, you should not have to pay to participate in a clinical trial. All study-related medication and assessments are usually provided free of charge.

What if I experience side effects?

The study team will monitor you very closely for any side effects. If you experience any problems, you should tell the study team immediately so they can assess you and provide appropriate care.

Cómo obtener más información

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.